- Company
- Novel targeted therapy for gastric cancer 'Vyloy' may launch
- by Eo, Yun-Ho May 9, 2024 05:52am
- 'Vyloy,' a targeted therapy for gastric cancer with a novel mechanism of action, is expected to be launched in South Korea. According to industry sources, Astellas Korea has submitted an application for approval of Vyloy (zolbetuximab), a treatment for claudin 18.2 (CLDN18.2) positive, HER2-negative, unresectable, advanced, or recurrent
- Company
- Novo Nordisk and Lilly post strong performance
- by Son, Hyung-Min May 8, 2024 05:48am
- The performance of Novo Nordisk and Eli Lilly, which released blockbuster diabetes and obesity drugs, have improved greatly in Q1 this year. Novo Nordisk's GLP-1 class diabetes drugs together generated KRW 10 trillion in quarterly sales. Lilly's obesity drug Zepbound posted sales of KRW 700 billion in Q1 this year, reaching nearly 1 trillion won
- Company
- Prescriptions for cephalosporin antibiotics double in 3yrs
- by Chon, Seung-Hyun May 8, 2024 05:48am
- The popularity of antibiotics in the outpatient prescription market continues. The prescription market for cephalosporin-class antibiotics has nearly doubled in the past 3 years. This ‘heyday’ in the cephalosporin prescription market is continuing, fueled by the steady increase in flu and cold cases since the end of the pandemic. According
- Company
- Another petition for reimb listing of TNBC drug 'Trodelvy'
- by Eo, Yun-Ho May 7, 2024 05:50am
- There is now yet another petition requesting reimbursement listing of the new breast cancer drug 'Trodelvy'. There was already a previous posting with 50,000 votes in January of last year. It appears that another petition was posted because it has been three months without any updates. A petitioner, who introduced themselves on the na
- Company
- Hyperparathyroidism drug Orkedia may be reimb in Q3
- by Eo, Yun-Ho May 7, 2024 05:50am
- ‘Orkedia,’ a drug for secondary hyperparathyroidism, has entered its final gateway to insurance reimbursement in Korea. According to industry sources, Kyowa Kirin Korea recently entered into pricing negotiations with the National Health Insurance Service for Orkedia (evocalcet), a new drug for secondary hyperparathyroidism that can deve
- Company
- Fate of Retevmo’s reimb in Korea receives attention
- by Eo, Yun-Ho May 3, 2024 06:00am
- No news has been heard of ever since its drug pricing negotiations broke down in August last year. However, RET inhibitors are a hard-to-forego treatment option for a small number of lung cancer patients. There are only 2 RET-targeted therapies &8211; ‘Gavreto (pralsetinib),’ which Roche Korea introduced from Blueprint Medicines, and
- Company
- Roche Korea appoints Ezat Azem as new general manager
- by Son, Hyung-Min May 3, 2024 05:52am
- Roche Korea announced that it had appointed Ezat Azem as the new general manager, effective as of May 1. The new GM first joined Roche’s Israel subsidiary in 1997, after which he served nearly 27 years in the group as a marketing division leader in Romania, Slovenia, and other countries around the world, contributing to the launch and gr
- Company
- 'Leclaza’s 5 counts of clinical results' to be showcased
- by Son, Hyung-Min May 2, 2024 05:53am
- It has been noted whether new anti-cancer candidates from the pharmaceutical and biotech industry in South Korea will be competitive on a global setting. According to industry sources on April 2nd, various Korean pharmaceutical companies, including Yuhan, HLB, and GI Innovation, will attend the 2024 American Society of Clinical Oncology
- Company
- Yuhan earns KRW253.2B through licensing-out deals in 5 yrs
- by Chon, Seung-Hyun May 2, 2024 05:52am
- Yuhan Corp has secured a solid source of revenue with technology licensing fees. Billions of won in profit have been steadily flowing in every quarter through technology licensing deals, the investing company’s development progress, and milestone payments. Yuhan Corp’s cumulative technology fee over the past 5 years amounted to KRW 253.2 billi
- Company
- Market withdrawal and indication transfer
- by Kim, Jin-Gu Apr 30, 2024 05:49am
- AstraZeneca Korea voluntarily withdrew approval for ‘Forxiga (dapagliflozin),’ an SGLT-2 inhibitor class diabetes treatment, and transferred the chronic heart failure·chronic kidney disease indication to its partnering company H.K. inno.N’s 'Dapa N.' Due to this clever co-promotion strategy between AstraZeneca Korea and HK inno.N, t
